1. Lapins J, Jarstrand C, Emtestam L. Coagulase-nega-tive staphylococci are the most common bacteria found in cultures from the deep portions of hi-dradenitis suppurativa lesions, as obtained by carbon dioxide laser surgery. Br J Dermatol 1999; Jan, 140(1):90-5

2. Clemmensen OJ. Topical treatment of hidradenitis suppurativa with clindamycin. Int J Dermatol 1983; 22:325-328

3. Jemec GB, Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hi-dradenitis suppurativa. J Am Acad Dermatol 1998; 39:971-974

4. Akhavan A, Bershad S. Topical acne drugs: review of clinical properties, systemic exposure, and safety. Am J Clin Dermatol 2003; 4:473-492

5. Krautheim A, Gollnick H. Transdermal penetration of topical drugs used in the treatment of acne. Clin Pharmacokinet 2003; 42:1287-1304

6. Parry MF, Rha CK. Pseudomembranous colitis caused by topical clindamycin phosphate. Arch Dermatol 1986; 122:583-584

7. Milstone EB, McDonald AJ, Scholhamer CF Jr. Pseudomembranous colitis after topical application of clindamycin. Arch Dermatol 1981; 117:154-155

8. Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, Leyden JJ, Shalita A, Thiboutot D. Management of acne. Topical retinoids. J Am Acad Dermatol 2003; 49 [Suppl 1]:S5-S11

9. Yu CC, Cook MG. Hidradenitis suppurativa: a disease of follicular epithelium rather than apocrine glands. Br J Dermatol 1990; 122:763-769

10. Attanoos R, Appleton MAC, Douglas-Jones AG. The pathogenesis of hidradenitis suppurativa: a closer look at apocrine and apoeccrine glands. Br J Dermatol 1995; 133:254-258

11. Boer J, Weltevreden EF. Hidradenitis suppurativa or acne inversa: a clinicopathological study of early lesions. Br J Dermatol 1996; 135:721-725

12. Boer J, Dijkstra AT, Baar TJM, Meer JB van der. Hidradenitis suppurativa (acne inversa): Lokale be-handeling met resorcine. Ned Tijdschr Derm Vene-reol 2001; 11:348-349

13. Boer J, Bos WH, Meer JB van der. Hidradenitis sup-purativa (acne inversa): behandeling met deroofing en resorcine [English abstract]. Ned Tijdschr Derm Venereol 2004; 14:274-278

14. Braun Falco O, Plewig G, Wolff HH, Burgdorf WHC. Diseases of the sebaceous Glands. In: Braun Falco O, Plewig G, Wolff HH, Burgdorf WHC (eds) Dermatology, 4th revised edn. Springer, Berlin Heidelberg New York, 1996; pp 1051-1082

15. Webster GF. Acne vulgaris. Br Med J 2002; 325:475479

16. Stienstra P. Hidradenitis suppurativa. In: Jansen LH (ed) Huid en geslachtsziekten. Scheltema en Holke-ma, Utrecht, 1975; pp 121-125

17. Polano MK. Topical therapeutics. Churchill Livingstone, Edinburgh, 1984

18. Groot de AC. Dermatological drugs, topical agents and cosmetics. In: Dukes MNG, Aronson JK (eds) Meyler's side effects of drugs, 14th edn. Elsevier, Amsterdam, 2000; p 473

19.Degreef H, Hulsebos HJ, Marien KJC, Schroeff JG van der. Behandelingsprincipes. In: Vloten WA, van, Degreef HJ, Stolz E, Vermeer BJ, Willemze R (eds) Dermatologie en Venereologie, 3rd edn. Elsevier, Amsterdam, 2000.

20. Mills OH, Kligman AM. Assay of comedolytic activity in acne patients. Acta Dermatovenereol 1982; 63:68-71

21. Mills OH, Kligman AM. Drugs that are ineffective in the treatment of acne vulgaris. Br J Dermatol 1983; 108:371-374

22. Wüthrich B, Zabrodsky S, Storck H. Perkutane Vergiftungen durch Resorcin, Salicylsäure und weisse Präcipitatsalbe. Pharmaceutica Acta Helvetiae 1970; 45:453-460

23. Häckh G, Schwarzmüller E. Codex dermatologischer Wirkstoffe. In: Niedner R, Ziegenmeyer J (eds) Dermatika. Wissenschaftliche Verlagsgesellschaft, Stuttgart, 1992; pp 447-448

24. Werth von der JM, Williams HC. The natural history of hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2000; 14:389-392

25. Cunliffe WJ. Looking back to the future - acne. Dermatology 2002; 204:167-172

26. Cassano N, Alessandrini G, Mastrolonardo M, Vena GA. Peeling agents: toxicological and allergo-logical aspects. J Eur Acad Dermatol Venereol 1999; 13:14-23

27. Bontemps H, Mallaret M, Besson G, Bochaton H, Carpentier F. Confusion after topical use of resor-cinol. Arch Dermatol 1995; 131:112

28. Cunningham AA. Resorcine poisoning. Arch Dis Child 1956; 31:173-176

29. Plas M van der, Bos WH. Chirurgische behandel-ing (epitheliale adnexcysten) door de dermatoloog [English abstract]. Ned Tijdschr Derm Venereol 1994; 4:101-103

30. Breathnach AS. Azelaic acid: potential as a general antitumoural agent. Med Hypotheses 1999; 52:221226

31. Brasch J, Christophers E. Azelaic acid has anti-mycotic properties in vitro. Dermatology 1993; 186:55-58

32. Detmar M, Mayer-da-Silva A, Stadler R, Orfanos CE. Effects of azelaic acid on proliferation and ultrastructure of mouse keratinocytes in vitro. J Invest Dermatol 1989; 93:70-74

33. Topert M, Rach P, Siegmund F. Pharmacology and toxicology of azelaic acid. Acta Dermatol Venereol Suppl (Stockh) 1989; 143:14-19

34. Passi S, Picardo M, Mingrone G, Breathnach AS, Nazzaro-Porro M. Azelaic acid - biochemistry and metabolism. Acta Dermatol Venereol Suppl (Stockh) 1989; 143:8-13

35. Galhaup I. Azelaic acid: mode of action at cellular and subcellular levels. Acta Dermatol Venereol Suppl (Stockh) 1989; 143:75-82

36. Bojar RA, Holland KT, Leeming JP, Cunliffe WJ. Azelaic acid: its uptake and mode of action in Staphylococcus epidermidis NCTC 11047. J Appl Bacteriol 1988; 64:497-504

37. Wilkinson JD. Fusidic acid in dermatology. Br J Dermatol 1998;139 [Suppl] 53:37-40

38. Levine RM, Rasmussen JE. Intralesional corticoste-roids in the treatment of nodulocystic acne. Arch Dermatol 1983; 119:480-481

39. Jansen T, Romiti R, Plewig G, Altmeyer P. Disfiguring draining sinus tracts in a female acne patient. Pediatr Dermatol 2000; 17:123-125

Chapter 22



Jan Lapins, Lennart Emtestam

Acne Attack

Acne Attack

This Book Below Will Show You Exactly What You Need To Beat Your Acne!

Get My Free Ebook

Post a comment